Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901369 | 0.84 | CYP2C19 (0.44) | DPP4KMT2AALOX5APFEN1PTGER1 | |
| SCHEMBL775057 | 0.82 | DPP4 (0.58) | DPP4PDCD1CD274KMT2ACA12 | |
| SCHEMBL776889 | 0.82 | DPP4 (0.58) | DPP4PDCD1CD274KMT2ACA12 | |
| SCHEMBL22342193 | 0.78 | CSNK2A2 (0.42) | ALOX5APFEN1ALDH1A1MAPK1LMNA | |
| SCHEMBL3083039 | 0.78 | MAPT (0.39) | KMT2AALOX5APFEN1LMNA | |
| SCHEMBL22342192 | 0.77 | FFAR1 (0.40) | PDCD1CD274ALOX5APFEN1HTR7 | |
| SCHEMBL15912540 | 0.75 | MAPK1 (0.42) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL10438531 | 0.75 | DPP4 (0.46) | DPP4PDCD1CD274KMT2ACA12 | |
| SCHEMBL328862 | 0.75 | DPP4 (0.60) | DPP4PDCD1CD274KMT2ACA12 | |
| SCHEMBL31261742 | 0.75 | DPP4 (0.60) | DPP4PDCD1CD274KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021129724-A1 | ARYLAMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | 陕西莱特光电材料股份有限公司 | 2021-07-01 | — | — | WO | disclosed |
| CN-107709496-A | The manufacture method of bonding agent, convered structure and convered structure | 株式会社可乐丽 | 2018-02-16 | — | — | CN | disclosed |
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | CEPHALON, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-7449481-B2 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1737815-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245747-A1 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005100308-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1586559-A1 | Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives | CEPHALON, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | AANAT, SNCA, NAT1 | DPP4 2664/4885PDCD1 4388/4885CD274 4792/4885 |
| US-20050245747-A1 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | TPH2, TPH1, AANAT | DPP4 1631/4885PDCD1 2621/4885CD274 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.